Visual Abstract

Objective: This CAPTURE post-hoc analysis identified patterns in the use of selected glucose-lowering agents (GLA) in people with T2D with or without CVD and by CVD risk factor prevalence.

Methods: CAPTURE was a cross-sectional, observational study in people with T2D across 13 countries. Participant information was collected during a single routine clinical visit in a primary/specialist setting between Dec 1, 2018 and Sep 31, 2019. Data were analyzed descriptively.

Results: Of 9823 participants, 3582 had a history of CVD (CVD group) and 6241 had no history of CVD (NoCVD group). Regardless of CVD status, use of GLA was more common in those who were males, aged 55-≤75 yrs, or who had a diabetes duration >10 yrs, HbA1c >7-<9%, diagnosed hypertension or an eGFR >60 ml/min/1.73m2. Newer agents (GLP-1 RAs and SGLT2is) were less prescribed versus insulins and sulfonylureas (SUs). Compared with NoCVD, use of newer agents was lower in people from CVD group who were aged <55 yrs or who were diagnosed with diabetes 10 yrs ago (Table).

Conclusion: Insulins and SUs were more frequently used than newer GLA, regardless of CVD status. The low use of newer agents, particularly in younger people with short diabetes duration, suggests delayed introduction despite recent guidelines for managing people with T2D and CVD or CV risk.

graphic
View largeDownload slide
Disclosure

G. Dieuzeide: Advisory Panel; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi, Speaker’s Bureau; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi. C.Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungária Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Wörwag Pharma. O.Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G.T.Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S.Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K.Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S.Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk. A. M. Alguwaihes: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi. J.A.Leon: Advisory Panel; Self; AstraZeneca, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Research Support; Self; Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Takeda Pharmaceutical Co., Speaker's Bureau; Self; AstraZeneca, Merck & Co., Inc., Merck Sharp & Dohme Corp., Novo Nordisk. F.Bayram: Advisory Panel; Self; Novo Nordisk A/S, Sanofi Genzyme, Consultant; Self; Lilly Diabetes, Novo Nordisk, Pfizer Inc. P.Darmon: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Mundipharma International, Novartis AG, Novo Nordisk, Sanofi. T. Davis: Advisory Panel; Self; Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; Novo Nordisk. Other Relationship; Self; Novo Nordisk. K.T. Eriksen: Employee; Self; Novo Nordisk. T. Hong: Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi. T.J. Jensen: Employee; Self; Novo Nordisk. C. Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungária Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Wörwag Pharma. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. Research Support; Self; AstraZeneca, Novo Nordisk. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G.T. Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S. Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K. Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S. Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk.

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.